Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA. For more information, visit www.thymmune.com.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $7M
Investors 1
| Date | Name | Website |
| - | NYBC Ventu... | nybcventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.03.2023 | Seed | $7M | - |
Mentions in press and media 4
| Date | Title | Description |
| 02.03.2023 | Thymmune Secures $7 Million in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal | Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced that it has secured $7 million in seed financing led by Pillar VC, with participation from N... |
| 01.03.2023 | Thymmune Raises $7M in Seed Financing | Thymmune Therapeutics, a Cambridge, MA-based biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, secured $7m in seed financing. The round was led by Pillar VC, with participation ... |
| 01.03.2023 | Thymmune Secures $7M in Seed Financing | CAMBRIDGE,MA,Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, has secured $7 million in seed financing. >> Click here for more funding data on... |
| - | Thymmune Therapeutics | “Thymmune Therapeutics” |